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Pandoraea species are considered as emerging pathogens in people with cystic fibrosis
(CF). The contribution of these organisms to disease progression in CF patients is not fully
understood owing in large measure to the scant reports in clinical and research literature
describing their colonization of CF patients and their associated virulence determinants.
In an effort to increase awareness and evidence for Pandoraea spp. infection in people
with CF, and to stimulate research aimed at unraveling the pathogenic properties of
Pandoraea, we report a case of a 26-year-old Australian (Tasmanian) man with CF
who was chronically infected with Pandoraea pnomenusa for at least one year prior to
his death from respiratory failure. In addition, we describe for the first time evidence
suggesting that this bacterium is a facultative anaerobe and report on the availability of
a whole genome sequence for this organism. To the best of our knowledge, this report
represents only the second clinical case study of P. pnomenusa infection in the world,
and the first in an Australian CF patient.
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CASE REPORT
In January 2013, a 26-year-old man with cystic fibrosis (CF, genotype homozygous F508del) and
a history of chronic mucoid Pseudomonas aeruginosa lung infection was admitted to the Royal
Hobart Hospital (RHH), Tasmania, Australia, with increasing malaise and left-sided pleuritic
chest pain. The patient was at the time on his eighth day of out-patient intravenous antibiotic
therapy for a respiratory exacerbation, which consisted of once daily tobramycin (560mg),
piperacillin/tazobactam (12 g of piperacillin component/24 h) as a continuous infusion, in addition
to his long-term azithromycin (500mg, orally three times a week) therapy.
On the day of admission he was afebrile with an oxygen saturation of 97% on 4 L/min O2 via
nasal cannulae, and his heart rate was 94 beats per minute with a blood pressure of 116/74 mmHg.
On physical examination, reduced breath sounds and inspiratory crackles were noted in the left
lower zone. In addition, his white cell count was elevated (19.7 × 109/L [normal range 3.5–11.0 ×
109/L]) with 80.2% neutrophils. A chest radiograph revealed a new andmoderately large left pleural
effusion. Computed tomography (CT) confirmed the multi-loculated left pleural effusion without
contrast enhancement, as well as collapse/consolidation in the basal left upper and lower lobes
(Figure 1). On the third day after admission a bronchoscopy and insertion of intercostal catheter
(ICC) was performed in theater and serous fluid drained from the ICC. During the bronchoscopy
copious purulent secretions were suctioned from the left bronchial tree and bronchial lavage
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FIGURE 1 | A computed tomography (CT) scan showed a
multi-loculated left pleural effusion.
performed. The bronchoscopy was complicated by respiratory
failure, and consequently the patient was transferred to the
intensive care unit (ICU) unit for mechanical ventilation.
No bacteria or fungi were able to be recovered from the
patient’s pleural fluid samples collected at that time. In contrast,
P. aeruginosa and Candida albicans were readily isolated from
the bronchial pus. Moreover, P. aeruginosa, C. albicans, and what
initially was determined to be a Pandoraea apista isolate, were all
readily cultured from a sputum sample collected from the patient
on the day of his admission to the RHH.
A repeat CT on the fourth day after the patient’s
admission showed a reduction in the volume of pleural
fluid, but worryingly also the interval development of
multiple bilateral foci of consolidation. His antibiotic
regimen was altered to include imipenem (1 g IV, 6
hourly) and cotrimoxazole (1600/320mg IV 6 hourly),
extending the spectrum of antibiotic cover to include
Pandoraea species. Due to the general lack of antibiotic
susceptibility data available for Pandoraea species, the
hospital recorded antibiotic susceptibility patterns of
the recovered Pandoraea isolate were interpreted using
EUCAST antibiotic breakpoint values that had previously been
determined for other more common CF pathogens (imipenem
susceptibility breakpoint for P. aeruginosa and cotrimoxazole
susceptibility breakpoint for Stenotrophomonas maltophilia,
for example).
On day five, video-assisted thoracoscopic surgery (VATS) was
performed; exploration of the left pleural space revealed extensive
fibrinopurulent material; and loculations were carefully divided
and a decortication performed. Histology from the visceral
pleural rind showed features of an organizing empyema. Despite
the addition of empirical antimicrobials, namely vancomycin
(1.5 g, 8 hourly) and caspofungin (70mg loading dose, then
50mg daily) there was no evident treatment response. Instead,
the patient had persisting fevers and could not be weaned from
ventilation.
A repeat bronchoscopy on day seven showed a much-reduced
volume of large airways secretions. A contemporaneous CT
showed progressive consolidation and increasing prominence
of widespread ground-glass opacities, suspicious for the
development of adult respiratory distress syndrome (ARDS).
Bronchial washings also showed persistence of mucoid
P. aeruginosa, C. albicans, and Pandoraea. In keeping with
an advanced directive, active treatment was withdrawn and
palliative care commenced. On the 11th day after his admission
to the RHH, the patient died.
MICROBIOLOGY
On a previous (December 2011) presentation to the RHH, a
multiple antibiotic resistant isolate was recovered from the
patient’s sputum sample that was streaked out on a Burkholderia
cepacia-selective medium. The isolate was presumptively
identified as a non-mucoid P. aeruginosa but was not stored.
In February 2012, the patient presented to a local private
hospital and a similar multi-resistant sputum isolate was
recovered. This isolate was retrospectively identified as P. apista
by matrix-assisted laser desorption ionization-time of flight
mass spectrometry (MALDI-TOF MS, Bruker Daltonics
GmbH, Leipzig, Germany) with a score of 2.049, which was
indicative of a reliable identification. The isolate was also
submitted to the Microbiological Diagnostic Unit Public
Health Laboratory (University of Melbourne, Australia) but
16S rRNA gene sequencing and phenotypic testing collectively
were only able to identify the isolate as belonging to the genus
Pandoraea.
In January 2013, the patient’s forced expiratory volume
in 1 second (FEV1) was lower (55% predicted) than his
previous measurement (of 60%, late 2012). Following this
diagnosis, the out-patient treatment regimen with tobramycin,
piperacillin/tazobactam, and azithromycin was continued.
A sputum culture obtained from the patient eight days
prior to his presentation and admission to the RHH (in
January 2013) showed that he had a persistent poly-microbial
airway infection, including P. aeruginosa, Staphylococcus
aureus, Streptococcus milleri group, C. albicans, and P. apista;
the identity of this P. apista isolate was confirmed by the
MALDI-TOF MS, at the RHH. The P. apista isolate was
subsequently demonstrated to be susceptible to the antibiotics
imipenem (by RHH staff) and cotrimoxazole but resistant to
ceftazidime, ciprofloxacin, gentamicin, tobramycin, piperacillin-
tazobactam, ticarcillin/clavulanic acid (timentin), aztreonam,
ceftriaxone, meropenem, colistin, and trimethoprim (Table 1).
It is noteworthy that the antibiotic susceptibility profile of this
P. apista isolate was similar to that obtained for the initial multi-
drug resistant isolate recovered from the patient’s sputum sample
(December 2011).
Interestingly, the CF lung environment is characterized by the
presence of hypoxic micro-niches yet the ability of Pandoraea
to colonize these niches is unknown. We demonstrated that
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TABLE 1 | P. pnomenusa antibiotic susceptibility testing by disk diffusion assay.
Antibiotic Disc content (µg) Zone diameter breakpoint for
Resistance (mm)
Inhibition zone
diameter (mm)
Resistant (R)/Susceptible
(S)
Meropenem 10 a18 0 R
Amikacin 30 a15 0 R
Ciprofloxacin 5 a22 0 R
Ceftazidime 10 a16 0 R
Ticarcillin-clavulanic acid 85 a18 8 R
Gentamicin 10 a15 0 R
Trimethoprim 5 – 0 –
Aztreonam 30 a16 0 R
Tobramycin 10 a16 0 R
Cefepime 30 a18 0 R
Piperacillin-tazobactam 36 a18 16 R
Trimethroprim-Sulphamethoxazole 25 b16 28.5 cS
aPseudomonas spp. breakpoint.
bStenotrophomonas maltophilia breakpoint.
cMinimum inhibitory concentration (MIC) of trimethoprim-sulfamethoxazole (cotrimoxazole, 12.5µg/ml) determined by the broth dilution method.
the P. apista isolates were able to grow under anaerobic
conditions. BHI agar plates supplemented with 1% potassium
nitrate were inoculated with Pandoraea cultures and incubated
in an anaerobic jar (containing an anaerobic sachet [AN0035;
AnaeroGen, Oxoid, UK] and anaerobic indicator) at 37◦C for five
days. While growth of the Pandoraea cultures was scant under
these conditions, it was nonetheless reproducible. Similarly,
Daneshvar et al. (2001) also reported on the growth of nine
Pandoraea isolates in a candle jar atmosphere. Collectively, these
data would seem to indicate that at least some Pandoraea species
might well be facultative anaerobes.
To gain an insight into the virulence mechanisms of
Pandoraea species, it was decided to sequence the genomes
of the two P. apista isolates recovered from this patient 11
months apart. Much to our surprise, the 16S rDNA sequence
component of the genomes from both the February 2012
and January 2013 isolates identified them as Pandoraea
pnomenusa (Ee et al., 2015). It is necessary to point out here that
misidentification of Pandoraea species byMALDI-TOFMS alone
is not uncommon because this method relies upon databases
that are generated for microorganisms routinely recovered from
clinical specimens. However, Pandoraea species are not routinely
isolated or identified by the conventional microbiological
methods available in many diagnostic laboratories; in turn,
this makes creation of databases for these organisms that are
necessary for accurate MALDI-TOF MS analyses somewhat
problematic (Fernández-Olmos et al., 2012a). On review of
the original MALDI-TOF MS identification scores, P. apista
scored highest (2.090) followed by P. pulmonicola (1.817)
and P. pnomenusa (1.614). The low score generated for P.
pnomenusa (i.e., <1.7) would likely have been interpreted
as being unreliable for species determination. The results
described in this case report further underscore the limitations
of using MALDI-TOF MS for differentiating Pandoraea
species and suggest that until such time comprehensive
databases are available, accurate identification of Pandoraea
species will be dependent upon molecular characterization
(Coenye and LiPuma, 2002; Schneider and Bauernfeind,
2015).
DISCUSSION
Cystic fibrosis (CF) is an autosomal recessive disease, which can
be caused by any one of the over 2000 mutations known to affect
the cystic fibrosis transmembrane conductance regulator (CFTR)
gene located on human chromosome 7. These mutations lead to
an absent or dysfunctional chloride ion channel in respiratory
epithelial cells, which in turn results in the accumulation of
viscous respiratory secretions in the lungs of people with CF
(Wilschanski et al., 1995). As a consequence, the airway of
CF patients is intrinsically susceptible to colonization by a
plethora of respiratory pathogens, and from very early on in
life is colonized by bacterial pathogens including S. aureus
and P. aeruginosa (Renders et al., 2001). These infections
inevitably lead to pulmonary exacerbations and lung function
decline. Despite aggressive antibiotic treatment, infection by
P. aeruginosa eventually becomes chronic and is responsible
for much of the morbidity and most of the mortality of
people with CF (Hauser et al., 2011). Intriguingly, many
“new” microorganisms are being isolated from and identified
in respiratory secretions collected from CF patients due in
part to improved laboratory diagnostic methods, although their
contributions to disease progression are not yet known.
One group of bacteria currently considered to be emerging
CF pathogens belongs to the genus Pandoraea. The genus
Pandoraea was described by Coenye et al. (2000) to differentiate
them from other already well-known CF pathogens, including
Pseudomonas and two closely related Gram-negative rods,
Burkholderia and Ralstonia species. In fact, phenotypic methods
used by many microbiology laboratories commonly lead to the
misidentification of Pandoraea species as either Burkholderia or
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Ralstonia species (Henry et al., 2001; Fernández-Olmos et al.,
2012b). Different species of Pandoraea have been described,
including P. apista, P. norimbergenesis, P. pnomenusa, P.
pulmonicola, and P. sputorum. There is great genotypic and
phenotypic diversity within species of Pandoraea but most have
thus far been demonstrated to be aerobic, non-spore forming,
non-nitrate-reducing, non-lactose-fermenting, Gram-negative
rods with a single polar flagellum (Stryjewski et al., 2003). In
addition, Pandoraea have been isolated from environmental
samples (soil, water; Coenye et al., 2000), as well as from
wound sites and variety of other clinical specimens including
sputum, lung tissue, and urine (Daneshvar et al., 2001; LiPuma,
2010). Importantly, P. apista has been isolated from the lungs
and blood cultures of CF patients (Stryjewski et al., 2003;
Johnson et al., 2004), demonstrating the invasive potential of this
Pandoraea species. However, there are few reports in the medical
literature describing the contribution of Pandoraea to disease
progression in CF patients. On this line, Jørgensen et al. (2003)
and Fernández-Olmos et al. (2012a) independently showed that
chronic bronchopulmonary colonization by either P. apista or
P. sputorum was associated with frequent exacerbations and
lung function decline in CF patients. Furthermore, Caraher
et al. (2008) demonstrated in vitro that infection of lung
cells by P. sputorum and other Pandoraea species induced a
strong proinflammatory response, with elevated interleukin-6
(IL-6) and interleukin-8 (IL-8) production. However, the precise
virulence mechanism(s) of Pandoraea responsible for provoking
proinflammatory responses in cells and leading to chronic
infection and disease in CF, as well as non-CF patients, remain
to be fully determined.
To gain an insight into the potential virulence mechanisms
of Pandoraea, our research group recently sequenced the whole
genome of the two P. pnomenusa (initially identified as P. apista)
isolates recovered 11 months apart from the patient being
discussed in this case report. Sequencing results showed that the
genomes of the two isolates were very similar, and differed only by
one gene that apparently encodes a predicted phage tail protein
(Ee et al., 2015). When we compared the genome sequence of
these clinical isolates to that of the environmental P. pnomenusa
strain RB38, we found that the clinical isolates possessed 152
unique genes (most of which were virulence genes) and were
missing 87 genes unique to the P. pnomenusa strain RB38. Many
of the 130 genes (∼105 open reading frames [ORFs]) predicted
to be associated with virulence and defense are indicated to
be involved with resistance to antibiotics and toxic compounds
(Ee et al., 2015), which is perhaps not too surprising given that
the P. pnomenusa isolates were demonstrated to be resistant
to multiple antibiotics. Major advances in our understanding
of the role(s) of Pandoraea in disease progression in CF rest
upon knowing the virulence properties of these organisms. In
this context, the whole genome sequences for P. pnomenusa
generated by our research group (Ee et al., 2015) and others
(Lim et al., 2016) provide a valuable resource, that could be
easily mined by researchers interested in forming a better
understanding of Pandoraea colonization in people with CF
and discovering potential therapeutic targets. In addition, our
results demonstrating that P. pnomenusa is a facultative anaerobe
are significant. It is well established that hypoxic micro-niches
are present in the CF lung, and that oxygen gradients across
the thick airway mucus (Worlitzsch et al., 2002; Tunney et al.,
2008) and oxygen consumption by polymorphonuclear cells and
bacteria (Kolpen et al., 2010) potentiate microaerophilic and even
anaerobic growth. It is therefore of high clinical significance
that P. pnomenusa seems to be able to grow under anaerobic
conditions, given that anaerobic growth appears to be associated
with increased persistence and antibiotic resistance in other
facultative anaerobes that infect the CF lung (Schobert and
Tielen, 2010).
CONCLUDING REMARKS
This case report further highlights the limitations associated
with using MALDI-TOF MS and phenotypic-based testing
for the identification of uncommon pathogens, and serves
as an important caution for laboratories relying on these
two methodologies for accurate identification of species of
Pandoraea. Without consistent and reliable species level
identification of multidrug-resistant Pandoraea, the clinical
significance of these organisms will remain difficult to
determine.
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